LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
Rhea-AI Summary
LifeMD (Nasdaq: LFMD) announced it is now offering Eli Lilly's oral GLP-1 pill Foundayo (orforglipron) through its weight management program via an integration with LillyDirect. The FDA approved Foundayo on April 1, 2026.
Foundayo is available to eligible patients with a starting self-pay price of $149/month, commercial patients may pay as little as $25/month with a Lilly savings card, and Medicare coverage is anticipated July 2026. LifeMD says the addition expands its branded GLP-1 offerings and supports virtual, clinically guided weight-management services.
Positive
- FDA approval of Foundayo on April 1, 2026
- Starting self-pay price of $149 per month
- Commercial patients may pay as little as $25 per month
- Medicare coverage anticipated July 2026
Negative
- Availability limited to eligible patients in LifeMD program
- Medicare coverage is anticipated, not yet confirmed
- Foundayo enters an already competitive oral GLP-1 market
News Market Reaction – LFMDP
In the Apr 10 session, LFMDP gained 0.63%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Product collaboration | Positive | +1.3% | Launch of Novo Nordisk Wegovy telehealth subscription with structured savings. |
| Mar 24 | Dividend declaration | Positive | +0.9% | Quarterly dividend declared on 8.875% Series A preferred shares. |
| Mar 16 | Leadership changes | Positive | +1.6% | Appointment of new CFO and expanded leadership team for growth. |
| Mar 09 | Earnings results | Positive | +2.5% | Reported 2025 revenue and EBITDA growth with strong cash position and subscribers. |
| Mar 03 | Conference participation | Neutral | -0.1% | Planned participation in two virtual healthcare investor conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive corporate and product updates have generally coincided with modestly positive price reactions over the last five news events.
Over the past six weeks, LifeMD reported strong 2025 results with revenue of $194.1M and adjusted EBITDA of $15.3M, launched a Wegovy® telehealth subscription program with savings up to $1,200 annually, and declared a preferred dividend of $0.5546875 per share. Leadership was strengthened with a new CFO and other senior appointments, and management attended investor conferences. These steps highlight a focus on scaling weight management offerings and corporate visibility, into which today’s Foundayo GLP-1 pill launch fits strategically.
Key Terms
glp-1 medical
oral glp-1 therapies medical
fda regulatory
medicare regulatory
cardiometabolic medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapies through LillyDirect®
NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that it is now offering Foundayo™ (orforglipron) to eligible patients through its weight management program. Foundayo, developed by Eli Lilly and Company, is a once daily oral treatment for adults with obesity or overweight with weight-related medical problems.
Foundayo is available to eligible LifeMD patients through the Company’s integration with LillyDirect®, which enables prescriptions to be fulfilled and shipped directly to patients. The starting self-pay price for Foundayo is
“The approval of Foundayo is another landmark moment in the treatment of obesity. Patients have access to a once-daily GLP-1 pill that may fit seamlessly into their lives,” said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. “By working with LillyDirect, we are able to offer eligible patients streamlined access to this therapy at an accessible price point. LifeMD remains dedicated to expanding access to high-quality, affordable weight management care, and the addition of Foundayo to our platform furthers that commitment.”
The addition of Foundayo expands LifeMD’s offerings of branded GLP-1 therapies from both Lilly and Novo Nordisk and reinforces LifeMD’s position as a leading destination for clinically guided weight management care with FDA-approved medications.
"The availability of Foundayo reflects Lilly's continued commitment to advancing clinical innovations for patients," said Laura Steele, Group Vice President of U.S. Cardiometabolic Health at Eli Lilly and Company. "We're committed to expanding access to treatment options through channels that meet patients where they are in their journey."
Foundayo is available to eligible patients through the LifeMD weight management program, which provides comprehensive support including virtual consultations with LifeMD’s dedicated clinical team, access to diagnostic testing, secure messaging through a personalized patient portal, and educational resources on diet and lifestyle changes that are important for sustained weight loss and metabolic health. Eligible patients can learn more and schedule a consultation at LifeMD.com.
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to expand access to high-quality, affordable care. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact
Atul Kavthekar, Chief Financial Officer
ir@lifemd.com
Media Contact
Jessica Friedeman, Chief Business Officer
press@lifemd.com
